The OHSU Cancer Institute is a matrix cancer center at Oregon Health &Science University (OHSU) in Portland, Oregon. In 1992, OHSU president Dr. Peter Kohler, committed to developing excellence in fundamental cancer research in this University, appointed Dr. Grover Bagby, a clinician scientist focusing on molecular hematopoiesis, as founding director of what then became the Oregon Cancer Center. The president, vice presidents, provost, and deans have provided resources that have steadily increased since that time. A Cancer Center Planning Grant (P20) was awarded in 1994, and the first CCSG award (P30) was made in 1997 and was then renewed in 2000. There are now 118 members of four scientific programs (Cancer Biology, Hematologic Malignancies, Solid Tumors, and Cancer Prevention and Control) holding 81 NCI grants, seven well-established shared resources, and three recently developed shared resources. All of the members of the Cancer Institute support our founding core principle that basic cancer research forms the strongest foundation for clinical research projects in cancer treatment, prevention, and control. Therefore, all members seek translational opportunities in their work. Center members perform outstanding research, convert research findings into treatments and preventive agents, and design clinical trials to validate molecular targets in the clinic. More than half of the patients participating in treatment trials are accrued to investigator-initiated studies. Our successes in translational research have changed the practice of oncology, have changed operating principles of discovery research for anticancer agents, and provide a new model by which clinical trials are attended by molecular target validation studies. Some of our discoveries in the past funding period have passed quickly through development and delivery stages and represent FDA-approved and well-validated standards of oncology practice internationally. National and international multi-institutional phase III trials led by our members have established new standards for cancer treatment and prevention. In the past funding period, we have recruited more than 40 new members, 17 of whom were recruited as a part of our strategic plan for development of epithelial malignancies. Many are now funded by the National Cancer Institute (NCI).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA069533-13S8
Application #
8137522
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1998-06-22
Project End
2011-07-19
Budget Start
2009-06-01
Budget End
2011-07-19
Support Year
13
Fiscal Year
2010
Total Cost
$99,985
Indirect Cost
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028

Showing the most recent 10 out of 277 publications